Skip to main content

Table 3 Overview of the studies reporting on the correlation between a preoperative nuclear imaging examination and the postoperative outcome liver failure

From: Nuclear imaging methods for the prediction of postoperative morbidity and mortality in patients undergoing localized, liver-directed treatments: a systematic review

Author

Liver failure defined

LF event rate

Preset cut-off value studied

Post hoc cut-off value established

Only descriptive analysis

Liver failure vs. no liver failure comparison

Key diagnostic characteristics reported

Cut-off value predictive in univariate regression analysis

Cut-off value predictive in multivariate regression analysis

Cieslak et al. [16]

Yes

2%

Yes

No

Yes

NR

NR

NR

NR

Cieslak et al. ≠ [17]

No

11%1

Yes

No2

Yes

NR

NR

NR

NR

Chapelle et al. [19]

Yes

14%

No

Yes

No

Yes

Yes

Yes

Yes

Chapelle et al. [20]

Yes

1%3

Yes

No

Yes

NR

NR

NR

NR

Chapelle et al. [21]

Yes

15%

Yes

No

No

Yes

Yes

NR

Yes

Chiba et al. [18]

Yes

6%4

Yes

No

No

NR

NR

Yes

Yes

Cho et al. [22]

Yes

5%

No

Yes

No

Yes

Yes

Yes

Yes

de Graaf et al. [10]

Yes

16%

No

Yes

No

Yes

Yes

NR

NR

Dinant et al. [24]

Yes

13%

No

Yes

No

Yes

Yes

Yes

Yes

Franken et al. [25]

Yes

15%5

Yes

No

Yes6

NR

NR

NR

NR

Guiu et al. [27]

Yes

0%

Yes

No

Yes

NR

NR

NR

NR

Hayashi et al. [28]

Yes

8%

Yes

No

No

NR

NR

Yes

NR

Hino et al. ≠ [29]7

Yes

4%

No

Yes

Yes

NR

NR

NR

NR

Hirai et al. [30]

Yes

23%

No

Yes

No

Yes

Yes

NR

NR

Hwang et al. ≠ [31]

No

9%

No

No

No

Yes

NR

NR

NR

Kaibori et al. [34]

Yes

8%

No

Yes

No

Yes

Yes

Yes

Yes

Kamohara et al. ≠ [35]

Yes

NR (30% overall)

Yes

No

Yes

NR

NR

NR

NR

Kato et al. ≠ [36]

Yes

33%8

No

Yes

No

Yes

Yes

NR

Yes

Katsuramaki et al. ≠ [37]7

Yes

3%

No

Yes

Yes

NR

NR

NR

NR

Kawamura et al. [38]

No

0%

No

No

Yes

NR

NR

NR

NR

Kim et al. ≠ [39]

No

10%

No

Yes

No

Yes

NR

NR

Yes

Kokudo et al. [40]

Yes9

13%

No

Yes

No

Yes

NR

NR

Yes

Kwon et al. [45]

Yes

5%

No

Yes

Yes

NR

NR

NR

NR

Mao et al. [48]

Yes10

13%

Yes

Yes

No

NR

Yes

NR

NR

Mitsumori et al. [49]

No11

10%

Yes

No

Yes

NR

NR

NR

NR

Nakamura et al. [50]

Yes

17%

No

Yes

No

Yes

NR

NR

Yes

Nakano et al. ≠ [51]

Yes

6%

Yes

No

No

Yes

NR

NR

No

Nanashima et al. ≠ [54]7

Yes

6%

No

Yes

No

Yes

NR

NR

NR

Nanashima et al. ≠ [55]

Yes

6%

No

Yes

No

Yes

NR

NR

No

Nanashima et al. ≠ [56]

Yes

8%

Yes (later group)

Yes (earlier group)

No

Yes

NR

Yes

No

Nanashima et al. ≠ [57]

Yes

5%

No

Yes

No

Yes

NR

NR

Yes (LF only)

Nanashima et al. [58]

No

4%

Yes

No

Yes

NR

NR

NR

NR

Nanashima et al. [59]

Yes

1%

No

No

No

Yes

NR

NR

NR

Nitta et al. [62]

Yes

18%

Yes

Yes

No

Yes

Yes

NR

Yes

Okabayashi et al. [63]

Yes

10%12

Yes

No

Yes

NR

NR

NR

NR

Okabe et al. [64]

Yes

PLD 7%

LF 2%

No

Yes (PLD)

No

Yes (PLD)

Yes (PLD)

NR

Yes (PLD)

Olthof et al. [65]

Yes

23%

Yes

Yes

No

Yes

Yes

Yes

Yes

Rassam et al. ≠[67]7

Yes

10% (LF only)

Yes

No

No

Yes

NR

NR

NR

Satoh et al. ≠ [68]7

Yes

9%

No

Yes

No

NR

Yes

NR

NR

Serenari et al. [69]

Yes

25%13

No

Yes

No

Yes

Yes

NR

NR

Serenari et al. [70]

Yes

33%

No

No

No

Yes

NR

NR

NR

Sugai et al. ≠ [73]

No

18%

No

No

No

Yes

NR

NR

NR

Sumiyoshi et al. [74]

Yes

7%14

Yes

No

No

Yes

NR

NR

NR

Sumiyoshi et al. [75]

Yes

0%

Yes

No

Yes

NR

NR

NR

NR

Tanaka et al. [79]

Yes

41%15

Yes

No

No

NR

NR

Yes

NR

Tanoue et al. [81]

Yes

15%

No

No16

No

Yes

NR

NR

NR

Truant et al. [82]

Yes

80%17

No

No

Yes

NR

NR

NR

NR

Truant et al. [83]

Yes

86%18

No

No

Yes

NR

NR

NR

NR

Yano et al. [88]

Yes

21%

No

No16

No

Yes

NR

NR

NR

Yoshida et al. [90]

Yes

6%

No

Yes

No

Yes

Yes

NR

Yes

Yumoto et al. [92]

No

19%

No

Yes

Yes

NR

NR

NR

NR

Yumoto et al. [93]

Yes9

17%

No

Yes

No

Yes

Yes

NR

NR

  1. Papers with liver failure as part of a composite endpoint are marked with a “≠”; in those cases, the data are reported for overall complications in which liver failure is included unless otherwise stated
  2. LF liver failure, PLD postoperative liver dysfunction
  3. 1Including three patients who died due to LF, but they only looked at the NMT in regard to developing LF postoperatively
  4. 2Not for the prediction of LF, but they establish a cut-off for the prediction of reaching a sufficient function of the FLR after PVE
  5. 31% of patients in the interventional group developed LF postoperatively, but in the 88 patients in the prior study by Chapelle et al., the liver failure rate was 14%, also reported in the table above
  6. 4Including two patients who died due to LF. Their primary endpoint was LF, but they also provided uptake values for the patients who died due to LF, also reported in mortality table
  7. 5In the overall population including the cohort from 2000 to 2015 and the cohort from 2016 to 2019
  8. 6Comparison of outcomes in the cohort from 2000 to 2015 to those in the cohort from 2016 to 2019 applying different cut-off values for the function of the FLR
  9. 7Cut-off value, diagnostic characteristics, predictive value, or LF vs. no LF for overall complications or poor outcome, but separate uptake values for patients who developed LF postoperatively
  10. 8Including 3 patients who died due to postoperative LF
  11. 9Signs of postoperative LF
  12. 10A Child Score > 9 is considered a high risk for developing LF
  13. 11Specifically described as hepatic insufficiency not LF
  14. 12Meeting the criteria for LF based on at least one of three definitions
  15. 13Including one patient who developed LF after stage 1 of the ALPPS procedure, and the other four patients developed LF after stage 2 of the ALPPS procedure
  16. 14LF-related Clavien-Dindo grade III complication
  17. 15Only in 98 patients who underwent hemi-hepatectomy did the authors evaluate mortality and LF. Therefore, the liver failure event rate was 40/98 (41%)
  18. 16Not for the prediction of LF, but they establish a cut-off for the prediction of postoperative long-term ascites
  19. 17Including one patient who developed LF and died postoperatively
  20. 18Postoperative clinical outcomes were only reported in the seven patients who underwent ALPPS. Six of the seven patients developed LF, five after stage 2 of the ALPPS procedure and one postoperatively who also died. The other five recovered postoperatively